

Lupien Pamela J
 Form 4
 June 19, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Lupien Pamela J

(Last) (First) (Middle)

ONE MEDIMMUNE WAY

(Street)

GAITHERSBURG, MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 MEDIMMUNE INC /DE [MEDI]

3. Date of Earliest Transaction
 (Month/Day/Year)
 06/18/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)

SVP, Human Resources

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	------------------------------------	--	---	------

Edgar Filing: Lupien Pamela J - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
				Code	V (A) (D)				
Stock Option (right to buy)	\$ 39.33	06/18/2007	D	30,000	(1)	04/01/2012	Common Stock	30,000	
Stock Option (right to buy)	\$ 29.34	06/18/2007	D	25,000	(2)	02/20/2013	Common Stock	25,000	
Stock Option (right to buy)	\$ 23.45	06/18/2007	D	30,000	(3)	03/04/2014	Common Stock	30,000	
Stock Option (right to buy)	\$ 24.17	06/18/2007	D	35,000	(4)	02/15/2015	Common Stock	35,000	
Stock Option (right to buy)	\$ 34.93	06/18/2007	D	15,000	(5)	11/08/2015	Common Stock	15,000	
Stock Option (right to buy)	\$ 36.78	06/18/2007	D	60,000	(6)	02/22/2016	Common Stock	60,000	
Stock Option (right to buy)	\$ 31.25	06/18/2007	D	60,000	(7)	02/14/2017	Common Stock	60,000	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lupien Pamela J ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878			SVP, Human Resources	

Signatures

/s/ William C. Bertrand, Jr.,
Attorney-in-Fact

06/19/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- This option, which provided for vesting with respect to 1/4 of the shares on 04/01/2003 and with respect to the remaining shares in equal
- (1) quarterly installments thereafter, was cancelled pursuant to the merger agreement between the issuer and AstraZeneca PLC in exchange for a cash payment of \$18.67 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (2) This option, which provided for vesting in equal quarterly installments beginning 05/20/2003, was cancelled in the merger in exchange for a cash payment of \$28.66 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (3) This option, which provided for vesting in equal quarterly installments beginning 6/4/2004, was cancelled in the merger in exchange for a cash payment of \$34.55 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (4) This option, which provided for vesting in equal quarterly installments beginning 05/16/2005, was cancelled in the merger in exchange for a cash payment of \$33.83 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (5) This option, which provided for vesting in equal quarterly installments beginning 02/9/2006, was cancelled in the merger in exchange for a cash payment of \$23.07 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (6) This option, which provided for vesting in equal quarterly installments beginning 5/23/2006, was cancelled in the merger in exchange for a cash payment of \$21.22 per share, representing the difference between the exercise price of the option and \$58.00 per share.
 - (7) This option, which provided for vesting in equal quarterly installments beginning 05/15/2007, was cancelled in the merger in exchange for a cash payment of \$26.75 per share, representing the difference between the exercise price of the option and \$58.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.